- Precigen, Inc. reported financial results for the third quarter and nine months ended September 30, 2025, highlighting third-quarter revenue of US$2.92 million versus US$953,000 a year earlier, alongside a net loss of US$146.34 million compared to US$23.98 million previously.
- While revenue more than tripled year-over-year, Precigen’s net loss also increased significantly, leading to a wider basic loss per share from continuing operations.
- We’ll explore how the company’s sharp rise in revenue yet widening losses impacts its overall investment narrative and growth outlook.
We've found 15 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
What Is Precigen's Investment Narrative?
For shareholders in Precigen, the big picture rests on the hope that its portfolio of innovative therapies, especially PAPZIMEOS for RRP, can eventually translate scientific achievement into sustained commercial success. The latest financials show a revenue jump, driven by product launches, but the sizable net loss highlights how high development and launch costs continue to strain the company despite its strong pipeline progress. The sharp spike in losses, revealed in the recent Q3 results, immediately ramps up questions around liquidity and cash burn, given earlier concerns about Precigen’s ability to remain a going concern. Notably, catalysts such as PAPZIMEOS’s market ramp or additional product approvals still matter most in the short term, but now, financial discipline and access to capital have become even greater near-term risks. The Q3 numbers underscore that the company’s future depends not just on growth but on managing very real operational pressures.
But with escalating losses, the risk around Precigen’s future funding needs has become more urgent. The valuation report we've compiled suggests that Precigen's current price could be inflated.Exploring Other Perspectives
Explore 10 other fair value estimates on Precigen - why the stock might be worth less than half the current price!
Build Your Own Precigen Narrative
Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.
- A great starting point for your Precigen research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
- Our free Precigen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Precigen's overall financial health at a glance.
No Opportunity In Precigen?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- Uncover the next big thing with financially sound penny stocks that balance risk and reward.
- Rare earth metals are the new gold rush. Find out which 36 stocks are leading the charge.
- This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Precigen might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com